Intellia Therapeutics Inc (NASDAQ: NTLA) is -27.62% lower on its value in year-to-date trading and has touched a low of $19.21 and a high of $37.15 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $20.67 in the last trading session, with the day’s gains setting it 1.4%.
Currently trading at $22.07, the stock is 0.07% and -5.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.39 million and changing 6.77% at the moment leaves the stock -14.17% off its SMA200. NTLA registered -37.83% loss for a year compared to 6-month loss of -19.80%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.60% gain in the last 1 month and extending the period to 3 months gives it a -14.98%, and is 11.92% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.12% over the week and 4.98% over the month.
Intellia Therapeutics Inc (NTLA) has around 526 employees, a market worth around $2.24B and $45.97M in sales. Profit margin for the company is -1106.87%. Distance from 52-week low is 14.89% and -40.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.07%).
The EPS is expected to grow by 0.57% this year.
Intellia Therapeutics Inc (NTLA) Top Institutional Holders
426.0 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 88.97% of the company’s shares. The shares outstanding are 101.58M, and float is at 99.78M with Short Float at 13.73%. Institutions hold 87.89% of the Float.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 12.1419% of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $214.79 million to account for 10.0496 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.5287% and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 5.0261 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
The most recent transaction is an insider sale by Clark Eliana, the company’s EVP, Chief Technical Officer. SEC filings show that Clark Eliana sold 405 shares of the company’s common stock on Jul 01 ’24 at a price of $22.93 per share for a total of $9287.0. Following the sale, the insider now owns 71470.0 shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Jun 17 ’24 that Verwiel Frank (Director) sold a total of 1,505 shares of the company’s common stock. The trade occurred on Jun 17 ’24 and was made at $25.00 per share for $37625.0. Following the transaction, the insider now directly holds 17948.0 shares of the NTLA stock.
Still, SEC filings show that on Mar 04 ’24, BASTA JAMES (EVP, General Counsel) disposed off 2,297 shares at an average price of $32.99 for $75778.0. The insider now directly holds 81,571 shares of Intellia Therapeutics Inc (NTLA).
